Silo Pharma Initiates $1M Share Buyback Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2025
0mins
Should l Buy SILO?
Silo Pharma's stock surged 40.11% in pre-market trading as it crossed above the 5-day SMA, following the approval of a $1 million share buyback program aimed at enhancing earnings per share and boosting investor confidence.
The buyback program is expected to reduce the number of shares outstanding, which could elevate the stock price and attract more investor interest. This strategic move comes as Silo Pharma focuses on integrating traditional therapeutics with psychedelic research, providing financial support for future R&D and market expansion efforts.
The positive market reaction, indicated by the significant pre-market price increase, reflects strong investor sentiment towards Silo Pharma's future prospects, potentially drawing in more institutional investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SILO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SILO
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Federal Initiatives Propel Innovation in Mental Health Treatments
- Federal Funding Support: U.S. federal agencies are providing funding through the EVIDENT program to institutions like Johns Hopkins University, indicating a strong commitment to advancing mental health treatments, which is expected to accelerate the development of psychedelic therapeutics.
- FDA New Drug Approval: The FDA has granted investigational new drug clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, further propelling the expansion of clinical-stage programs in the mental health sector.
- Priority Treatment Programs: The FDA issued three National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a focus on PTSD-related initiatives aimed at addressing urgent needs among veterans and broader patient populations.
- Guidance Release Imminent: The FDA confirmed that final guidance for psychedelic drug development will be published soon, a long-awaited milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways, facilitating the development of a new generation of therapies.
See More
Silo Pharma Expands into AI Technology Business
- Strategic Business Expansion: Silo Pharma has announced the acquisition of Qwikagents.ai's assets, marking its entry into the AI technology sector, aiming to enhance business diversity by providing autonomous AI agents for task execution.
- Significant Market Potential: According to MarketsandMarkets.com, the AI agent market is projected to reach between $47 billion and $53 billion by 2030, indicating a growth of approximately six times in the next four years, showcasing substantial business opportunities.
- Core Therapeutic Focus: Silo Pharma concentrates on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with existing products like SPC-15 for PTSD and SP-26 for Fibromyalgia, demonstrating a solid foundation in the biopharmaceutical sector.
- Notable Stock Volatility: SILO's stock has traded between $0.22 and $1.18 over the past year, closing at $0.56 on Wednesday with an 8.13% decline, and further dropping 7.67% to $0.52 in after-hours trading, reflecting market caution regarding its new strategic direction.
See More
Silo Pharma Advances Psychedelic Therapies for Mental Health
- Therapy Development: Silo Pharma announced plans to advance psychedelic-based therapies, particularly SPC-15 for treating post-traumatic stress disorder (PTSD), following an executive order issued by the U.S. government on April 18, 2026, aimed at accelerating research and patient access to mental health treatments.
- SPC-15 Overview: SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist delivered via an intranasal system, allowing for rapid delivery to the central nervous system, thus providing effective prophylactic treatment for PTSD patients and showcasing its potential in the mental health sector.
- Regulatory Pathway: The program is being advanced under the 505(b)(2) regulatory pathway to streamline the development timeline, enabling the company to enter clinical trials more quickly, with plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
- Market Reaction: SILO shares closed at $0.51 on Friday, up 1.18%, and are trading at $0.52 in premarket, up 0.95%, indicating a positive market response to the company's new strategic direction.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
SPC-15 PTSD Program Aligns with Federal Push for Mental Health Therapies
- Policy Acceleration: On April 18, 2026, President Trump signed an executive order directing multiple U.S. agencies to expedite research into psychedelic therapies for mental health, indicating a national focus that could create a more favorable regulatory environment for Silo Pharma's SPC-15 program.
- Innovative Treatment Approach: SPC-15, designed as a novel 5-HT4 receptor agonist, targets prophylactic treatment for PTSD and utilizes rapid nose-to-brain delivery to enhance therapeutic effects and patient compliance, potentially revolutionizing mental health treatment outcomes.
- Significant Market Opportunity: The global mental health therapeutics market is expanding, with PTSD affecting millions annually; the growing acceptance of psychedelic-assisted therapies may unlock new treatment paradigms and commercial opportunities, positioning Silo Pharma favorably in this evolving landscape.
- Clear R&D Strategy: Silo Pharma has licensed intellectual property for SPC-15 from Columbia University and is preparing for FDA IND engagement, demonstrating a strategic focus on drug delivery and clinical development aimed at leveraging evolving regulatory frameworks to accelerate innovation.
See More
Silo Pharma Secures Patent for PTSD Therapy
- Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
- Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
- Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
- Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.
See More
Federal Initiatives Propel Innovation in Mental Health Treatments
- Federal Funding Support: U.S. federal agencies are providing funding through the EVIDENT program to institutions like Johns Hopkins University, indicating a strong commitment to advancing mental health treatments, which is expected to accelerate the development of psychedelic therapeutics.
- FDA New Drug Approval: The FDA has granted investigational new drug clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, further propelling the expansion of clinical-stage programs in the mental health sector.
- Priority Treatment Programs: The FDA issued three National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a focus on PTSD-related initiatives aimed at addressing urgent needs among veterans and broader patient populations.
- Guidance Release Imminent: The FDA confirmed that final guidance for psychedelic drug development will be published soon, a long-awaited milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways, facilitating the development of a new generation of therapies.
See More
Silo Pharma Expands into AI Technology Business
- Strategic Business Expansion: Silo Pharma has announced the acquisition of Qwikagents.ai's assets, marking its entry into the AI technology sector, aiming to enhance business diversity by providing autonomous AI agents for task execution.
- Significant Market Potential: According to MarketsandMarkets.com, the AI agent market is projected to reach between $47 billion and $53 billion by 2030, indicating a growth of approximately six times in the next four years, showcasing substantial business opportunities.
- Core Therapeutic Focus: Silo Pharma concentrates on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with existing products like SPC-15 for PTSD and SP-26 for Fibromyalgia, demonstrating a solid foundation in the biopharmaceutical sector.
- Notable Stock Volatility: SILO's stock has traded between $0.22 and $1.18 over the past year, closing at $0.56 on Wednesday with an 8.13% decline, and further dropping 7.67% to $0.52 in after-hours trading, reflecting market caution regarding its new strategic direction.
See More
Silo Pharma Advances Psychedelic Therapies for Mental Health
- Therapy Development: Silo Pharma announced plans to advance psychedelic-based therapies, particularly SPC-15 for treating post-traumatic stress disorder (PTSD), following an executive order issued by the U.S. government on April 18, 2026, aimed at accelerating research and patient access to mental health treatments.
- SPC-15 Overview: SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist delivered via an intranasal system, allowing for rapid delivery to the central nervous system, thus providing effective prophylactic treatment for PTSD patients and showcasing its potential in the mental health sector.
- Regulatory Pathway: The program is being advanced under the 505(b)(2) regulatory pathway to streamline the development timeline, enabling the company to enter clinical trials more quickly, with plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
- Market Reaction: SILO shares closed at $0.51 on Friday, up 1.18%, and are trading at $0.52 in premarket, up 0.95%, indicating a positive market response to the company's new strategic direction.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
SPC-15 PTSD Program Aligns with Federal Push for Mental Health Therapies
- Policy Acceleration: On April 18, 2026, President Trump signed an executive order directing multiple U.S. agencies to expedite research into psychedelic therapies for mental health, indicating a national focus that could create a more favorable regulatory environment for Silo Pharma's SPC-15 program.
- Innovative Treatment Approach: SPC-15, designed as a novel 5-HT4 receptor agonist, targets prophylactic treatment for PTSD and utilizes rapid nose-to-brain delivery to enhance therapeutic effects and patient compliance, potentially revolutionizing mental health treatment outcomes.
- Significant Market Opportunity: The global mental health therapeutics market is expanding, with PTSD affecting millions annually; the growing acceptance of psychedelic-assisted therapies may unlock new treatment paradigms and commercial opportunities, positioning Silo Pharma favorably in this evolving landscape.
- Clear R&D Strategy: Silo Pharma has licensed intellectual property for SPC-15 from Columbia University and is preparing for FDA IND engagement, demonstrating a strategic focus on drug delivery and clinical development aimed at leveraging evolving regulatory frameworks to accelerate innovation.
See More
Silo Pharma Secures Patent for PTSD Therapy
- Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
- Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
- Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
- Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.
See More
